Successful dose reduction of dupilumab in atopic dermatitis
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad011 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Michael R Ardern-Jones und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Southampton NHS Foundation Trust. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Current UK, European and USA atopic dermatitis guidelines do not currently advise on the possibility of dose reduction of dupilumab therapy below the licensed dose of 300 mg subcutaneously every 2 weeks for adults. Here, we report preliminary findings to suggest that in those who respond well to the licensed dose, dupilumab dosing can be reduced while maintaining good disease control. We propose a randomized controlled clinical trial to further analyse the cost effectiveness of this approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Southampton NHS Foundation Trust.
- Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, Hampshire SO16 1DU, UK.
ORCID-Profile: Michael R Ardern-Jones
Zitieren
APA
Ardern-Jones, M. R., Buchanan, E. E., Njungu, S., & O'Driscoll, D. (2023). Successful dose reduction of dupilumab in atopic dermatitis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad011
Vancouver
Ardern-Jones MR, Buchanan EE, Njungu S, O'Driscoll D. Successful dose reduction of dupilumab in atopic dermatitis. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad011
BibTeX
@article{ArdernJones2023,
author = {Ardern-Jones, Michael R and Buchanan, Emily E and Njungu, Samba and O'Driscoll, Daniel},
title = {Successful dose reduction of dupilumab in atopic dermatitis},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad011}
}
EUVIMED